Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06152094 · ClinicalTrials.gov registry record · NA

UCSF BP Activate Letter Study

A NA study, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
484
Enrollment target

NCT06152094: Completed NA study, sponsored by University of California, San Francisco.

NCT06152094 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 484 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06152094, a NA study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
484 participants
Enrollment target

Study Summary

The BP Activate Study aims to assess the effectiveness of the BP Report letter with personalized BP medication recommendations, compared with Control letters and no intervention, at shortening time to appointment, time to visit, time to medication change, and time to achievement of BP goal.

Primary Outcome

Time is measured as number of days between randomization date and the day that a participant is prescribed a new anti-HTN medication or an increase in dose of a prior anti-HTN medication, or they have a documented BP measurement \<140 mmHg systolic and \<90 mmHg diastolic.

Interventions

  • OTHER BP Activate Letter
  • OTHER Control Letter

Trial Details

FieldValue
Enrollment Target 484 participants
Start Date 2023-07-20
Est. Completion 2024-12-31
Phase NA

What the finished NCT06152094 record still lists

NCT06152094 is an interventional study that assigns participants to a tested intervention. The registered 484 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (66% lower).

The record links to 0 conditions, and to 2 interventions - of which BP Activate Letter is the first listed.

NCT06152094 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06152094 about?

NCT06152094 is a clinical study titled "UCSF BP Activate Letter Study". The BP Activate Study aims to assess the effectiveness of the BP Report letter with personalized BP medication recommendations, compared with Control letters and no intervention, at shortening time to appointment, time to visit, time to medication change, and time to achievement of BP goal.

What is the current status of trial NCT06152094?

This trial is currently completed. It is a NA study. The enrollment target is 484 participants. The study started on 2023-07-20. Estimated completion is 2024-12-31.

What interventions are being tested in trial NCT06152094?

The interventions under investigation include: BP Activate Letter (OTHER), Control Letter (OTHER).

Who is sponsoring clinical trial NCT06152094?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06152094's enrollment target sits among peer trials

484 216th of 2000 higher than 1,785 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05421741 · 484 participants · Phase 4

    Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

  • NCT07124910 · 485 participants · Phase 3

    Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases

  • NCT02871726 · 483 participants · NA

    Transrectal Ultrasound Robot-Assisted Prostate Biopsy

  • NCT06420531 · 486 participants · NA

    Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06152094, the US trial registry maintained by the National Library of Medicine. NCT06152094 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.